Last updated: 11/07/2018 18:53:17
A Four-Week, Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multi Center Study of VENTOLIN HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to <48 months with Asthma Symptoms (i.e.wheeze, cough, dyspnea or chest tightness) consistent with Bronchospasm or Obstructive Airway Disease
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Four-Week, Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multi Center Study of VENTOLIN HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to <48 months with Asthma Symptoms (i.e.wheeze, cough, dyspnea or chest tightness) consistent with Bronchospasm or Obstructive Airway Disease
Trial description: A Four-Week, Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multi Center Study of VENTOLIN HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to <48 months with Asthma Symptoms (i.e.wheeze, cough, dyspnea or chest tightness) consistent with Bronchospasm or Obstructive Airway Disease
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Crim C, Lincourt W, Trivedi R, Ellsworth A, Davis-Allen A, Ventolin HFA MDI Safety in Children 24=<48 Months Old with Symptoms Of Bronchospasm, GlaxoSmithKline, RTP, NC. Poster presentation at the 2005 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, to be held March 18-22, 2005 in San Antonio, TX.
Medical condition
Asthma
Product
salbutamol
Collaborators
Not applicable
Study date(s)
May 2003 to December 2003
Type
Not applicable
Phase
1/2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2003-10-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website